U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C16H14F3N5O
Molecular Weight 349.3111
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of VORICONAZOLE

SMILES

C[C@@]([H])(c1c(cncn1)F)[C@](Cn2cncn2)(c3ccc(cc3F)F)O

InChI

InChIKey=BCEHBSKCWLPMDN-MGPLVRAMSA-N
InChI=1S/C16H14F3N5O/c1-10(15-14(19)5-20-7-22-15)16(25,6-24-9-21-8-23-24)12-3-2-11(17)4-13(12)18/h2-5,7-10,25H,6H2,1H3/t10-,16+/m0/s1

HIDE SMILES / InChI

Molecular Formula C16H14F3N5O
Molecular Weight 349.3111
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment:: http://www.drugbank.ca/drugs/DB00582

Voriconazole (vor-i-KON-a-zole, brand name Vfend, Pfizer) is a triazole antifungal medication. VFEND® (voriconazole) is available as film-coated tablets for oral administration, and as a lyophilized powder for solution for intravenous infusion. Voriconazole is a triazole antifungal agent indicated for use in the treatment of fungal infections including invasive aspergillosis, esophageal candidiasis, and serious fungal infections caused by Scedosporium apiospermum (asexual form of Pseudallescheria boydii) and Fusarium spp. including Fusarium solani. Fungal plasma membranes are similar to mammalian plasma membranes, differing in having the nonpolar sterol ergosterol, rather than cholesterol, as the principal sterol. Membrane sterols such as ergosterol provide structure, modulation of membrane fluidity, and possibly control of some physiologic events. Voriconazole effects the formation of the fungal plasma membrane by indirectly inhibiting the biosynthesis of ergosterol. This results in plasma membrane permeability changes and inhibition of growth. The primary mode of action of voriconazole is the inhibition of fungal cytochrome P-450-mediated 14 alpha-lanosterol demethylation, an essential step in fungal ergosterol biosynthesis. The accumulation of 14 alpha-methyl sterols correlates with the subsequent loss of ergosterol in the fungal cell wall and may be responsible for the antifungal activity of voriconazole. Voriconazole has been shown to be more selective for fungal cytochrome P-450 enzymes than for various mammalian cytochrome P-450 enzyme systems. The most common side effects associated with voriconazole include transient visual disturbances, fever, rash, vomiting, nausea, diarrhea, headache, sepsis, peripheral edema, abdominal pain, and respiratory disorder. Unlike most adverse effects, which are similar to other azole antifungal agents, visual disturbances (such as blurred vision or increased sensitivity to light) are unique to voriconazole. Though rare, there have been cases of serious hepatic reactions during treatment with voriconazole (a class effect of azole antifungal agents). Liver function tests should be evaluated at the start of and during the course of therapy. Voriconazole is phototoxic. It has been associated with an increased risk of squamous-cell carcinoma of the skin

Originator

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
VFEND

Approved Use

use in the treatment of the fungal infections

Launch Date

1070841600000
Curative
VFEND

Approved Use

use in the treatment of the fungal infections

Launch Date

1070841600000
Curative
VFEND

Approved Use

use in the treatment of the fungal infections

Launch Date

1070841600000
Curative
VFEND

Approved Use

use in the treatment of the fungal infections

Launch Date

1070841600000
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
3.13 μg/mL
6 mg/kg single, intravenous
dose: 6 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
VORICONAZOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
2.31 μg/mL
200 mg 2 times / day multiple, oral
dose: 200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
VORICONAZOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
3.03 μg/mL
3 mg/kg 2 times / day steady-state, intravenous
dose: 3 mg/kg
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
VORICONAZOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
4.77 μg/mL
4 mg/kg 2 times / day steady-state, intravenous
dose: 4 mg/kg
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
VORICONAZOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
4.74 μg/mL
300 mg 2 times / day multiple, oral
dose: 300 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
VORICONAZOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
2.3 μg/mL
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
VORICONAZOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
3.1 μg/mL
200 mg 2 times / day steady-state, oral
dose: 200 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
VORICONAZOLE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
13.9 μg × h/mL
6 mg/kg single, intravenous
dose: 6 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
VORICONAZOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
12.4 μg × h/mL
200 mg 2 times / day multiple, oral
dose: 200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
VORICONAZOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
13.7 μg × h/mL
3 mg/kg 2 times / day steady-state, intravenous
dose: 3 mg/kg
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
VORICONAZOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
33.9 μg × h/mL
4 mg/kg 2 times / day steady-state, intravenous
dose: 4 mg/kg
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
VORICONAZOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
34 μg × h/mL
300 mg 2 times / day multiple, oral
dose: 300 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
VORICONAZOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
9.31 μg × h/mL
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
VORICONAZOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
27.9 μg × h/mL
200 mg 2 times / day steady-state, oral
dose: 200 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
VORICONAZOLE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
15.5 h
200 mg 2 times / day steady-state, oral
dose: 200 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
VORICONAZOLE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
42%
200 mg 2 times / day multiple, oral
dose: 200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
VORICONAZOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
42%
300 mg 2 times / day multiple, oral
dose: 300 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
VORICONAZOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
16 mg/kg 1 times / day steady, oral
Recommended
Dose: 16 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 16 mg/kg, 1 times / day
Sources:
unhealthy, 17 years
Health Status: unhealthy
Age Group: 17 years
Sex: F
Sources:
Disc. AE: Photophobia, Fatigue...
AEs leading to
discontinuation/dose reduction:
Photophobia (1 patient)
Fatigue (1 patient)
Concentration impaired (1 patient)
Insomnia (1 patient)
Sources:
200 mg 2 times / day steady, oral
Recommended
Dose: 200 mg, 2 times / day
Route: oral
Route: steady
Dose: 200 mg, 2 times / day
Sources:
unhealthy, 42.7–64.5 years
Health Status: unhealthy
Age Group: 42.7–64.5 years
Sex: M+F
Sources:
Disc. AE: Function liver abnormal, Hallucination, visual...
AEs leading to
discontinuation/dose reduction:
Function liver abnormal (73 patients)
Hallucination, visual (16 patients)
Skin rash (6 patients)
Kidney dysfunction (3 patients)
Electrocardiogram QTc interval prolonged (2 patients)
Gastrointestinal symptom NOS (1 patient)
Sources:
400 mg single, oral
Overdose
Dose: 400 mg
Route: oral
Route: single
Dose: 400 mg
Sources:
unhealthy, 53.4–67.5 years
Health Status: unhealthy
Age Group: 53.4–67.5 years
Sex: M+F
Sources:
Disc. AE: CRP increased, Bilirubin increased...
AEs leading to
discontinuation/dose reduction:
CRP increased (31 patient)
Bilirubin increased (31 patient)
Sources:
16 mg/kg 1 times / day steady, oral
Recommended
Dose: 16 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 16 mg/kg, 1 times / day
Sources:
unhealthy, 9 years
Health Status: unhealthy
Age Group: 9 years
Sex: M
Sources:
Disc. AE: Photophobia...
AEs leading to
discontinuation/dose reduction:
Photophobia (1 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
Concentration impaired 1 patient
Disc. AE
16 mg/kg 1 times / day steady, oral
Recommended
Dose: 16 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 16 mg/kg, 1 times / day
Sources:
unhealthy, 17 years
Health Status: unhealthy
Age Group: 17 years
Sex: F
Sources:
Fatigue 1 patient
Disc. AE
16 mg/kg 1 times / day steady, oral
Recommended
Dose: 16 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 16 mg/kg, 1 times / day
Sources:
unhealthy, 17 years
Health Status: unhealthy
Age Group: 17 years
Sex: F
Sources:
Insomnia 1 patient
Disc. AE
16 mg/kg 1 times / day steady, oral
Recommended
Dose: 16 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 16 mg/kg, 1 times / day
Sources:
unhealthy, 17 years
Health Status: unhealthy
Age Group: 17 years
Sex: F
Sources:
Photophobia 1 patient
Disc. AE
16 mg/kg 1 times / day steady, oral
Recommended
Dose: 16 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 16 mg/kg, 1 times / day
Sources:
unhealthy, 17 years
Health Status: unhealthy
Age Group: 17 years
Sex: F
Sources:
Gastrointestinal symptom NOS 1 patient
Disc. AE
200 mg 2 times / day steady, oral
Recommended
Dose: 200 mg, 2 times / day
Route: oral
Route: steady
Dose: 200 mg, 2 times / day
Sources:
unhealthy, 42.7–64.5 years
Health Status: unhealthy
Age Group: 42.7–64.5 years
Sex: M+F
Sources:
Hallucination, visual 16 patients
Disc. AE
200 mg 2 times / day steady, oral
Recommended
Dose: 200 mg, 2 times / day
Route: oral
Route: steady
Dose: 200 mg, 2 times / day
Sources:
unhealthy, 42.7–64.5 years
Health Status: unhealthy
Age Group: 42.7–64.5 years
Sex: M+F
Sources:
Electrocardiogram QTc interval prolonged 2 patients
Disc. AE
200 mg 2 times / day steady, oral
Recommended
Dose: 200 mg, 2 times / day
Route: oral
Route: steady
Dose: 200 mg, 2 times / day
Sources:
unhealthy, 42.7–64.5 years
Health Status: unhealthy
Age Group: 42.7–64.5 years
Sex: M+F
Sources:
Kidney dysfunction 3 patients
Disc. AE
200 mg 2 times / day steady, oral
Recommended
Dose: 200 mg, 2 times / day
Route: oral
Route: steady
Dose: 200 mg, 2 times / day
Sources:
unhealthy, 42.7–64.5 years
Health Status: unhealthy
Age Group: 42.7–64.5 years
Sex: M+F
Sources:
Skin rash 6 patients
Disc. AE
200 mg 2 times / day steady, oral
Recommended
Dose: 200 mg, 2 times / day
Route: oral
Route: steady
Dose: 200 mg, 2 times / day
Sources:
unhealthy, 42.7–64.5 years
Health Status: unhealthy
Age Group: 42.7–64.5 years
Sex: M+F
Sources:
Function liver abnormal 73 patients
Disc. AE
200 mg 2 times / day steady, oral
Recommended
Dose: 200 mg, 2 times / day
Route: oral
Route: steady
Dose: 200 mg, 2 times / day
Sources:
unhealthy, 42.7–64.5 years
Health Status: unhealthy
Age Group: 42.7–64.5 years
Sex: M+F
Sources:
Bilirubin increased 31 patient
Disc. AE
400 mg single, oral
Overdose
Dose: 400 mg
Route: oral
Route: single
Dose: 400 mg
Sources:
unhealthy, 53.4–67.5 years
Health Status: unhealthy
Age Group: 53.4–67.5 years
Sex: M+F
Sources:
CRP increased 31 patient
Disc. AE
400 mg single, oral
Overdose
Dose: 400 mg
Route: oral
Route: single
Dose: 400 mg
Sources:
unhealthy, 53.4–67.5 years
Health Status: unhealthy
Age Group: 53.4–67.5 years
Sex: M+F
Sources:
Photophobia 1 patient
Disc. AE
16 mg/kg 1 times / day steady, oral
Recommended
Dose: 16 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 16 mg/kg, 1 times / day
Sources:
unhealthy, 9 years
Health Status: unhealthy
Age Group: 9 years
Sex: M
Sources:
Overview

OverviewOther

Other InhibitorOther SubstrateOther Inducer








Drug as perpetrator​Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
major
yes (co-administration study)
Comment: from FDA label pp26-28: rifampin decreased voriconazole Cmax by 93% and AUC by 96% and fluconazole increased voriconazole Cmax by 57% and AUC 79%
Page: 2, 10,13, 21-23, 26-27
no
no
no
yes [Km 21 uM]
yes (co-administration study)
Comment: from FDA label pp26-28: rifampin decreased voriconazole Cmax by 93% and AUC by 96%; fluconazole increased voriconazole Cmax by 57% and AUC 79%
Page: 11
yes [Km 240 uM]
yes (co-administration study)
Comment: from FDA label pp26-28: rifampin decreased voriconazole Cmax by 93% and AUC by 96%; fluconazole increased voriconazole Cmax by 57% and AUC 79%
Page: 11
PubMed

PubMed

TitleDatePubMed
Improving the outcome of invasive aspergillosis: new diagnostic tools and new therapeutic strategies.
2002
Pharmacological aspects of the new triazole voriconazole.
2002
Successful treatment of Candida glabrata myocarditis with voriconazole.
2002
Voriconazole: in the treatment of invasive aspergillosis.
2002
Successful treatment of Paecilomyces lilacinus endophthalmitis with voriconazole.
2002
Influence of voriconazole and fluconazole on Candida albicans in long-time continuous flow culture.
2002
Gateways to Clinical Trials.
2002 Apr
Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.
2002 Aug 8
Use of voriconazole to successfully treat disseminated Trichosporon asahii infection in a patient with acute myeloid leukaemia.
2002 Dec
Usefulness of a colorimetric method for testing antifungal drug susceptibilities of Aspergillus species to voriconazole.
2002 Dec
Voriconazole in the management of invasive aspergillosis in two patients with acute myeloid leukemia undergoing stem cell transplantation.
2002 Dec
Case Reports. Chronic and acute Aspergillus meningitis.
2002 Dec
Voriconazole versus amphotericin B for invasive aspergillosis.
2002 Dec 19
Voriconazole versus amphotericin B for invasive aspergillosis.
2002 Dec 19
In vitro activity of three new triazoles and one echinocandin against Candida bloodstream isolates from cancer patients.
2002 Jul
Fungal keratitis caused by Scedosporium apiospermum: report of two cases and review of treatment.
2002 Jul
Severe keratomycosis secondary to Scedosporium apiospermum.
2002 Jul
Antifungal triazoles and polymorphonuclear leukocytes synergize to cause increased hyphal damage to Scedosporium prolificans and Scedosporium apiospermum.
2002 Jul
Voriconazole.
2002 Jul 22
Effect of medium composition on static and cidal activity of amphotericin B, itraconazole, voriconazole, posaconazole and terbinafine against Aspergillus fumigatus: a multicenter study.
2002 Jun
Invasive Aspergillus infections in hematologic malignancy patients.
2002 Jun
New drugs, old drugs - dear drugs, cheap drugs.
2002 Jun 15
Broth medium for microdilution susceptibility tests of fluconazole and voriconazole.
2002 May
Voriconazole versus liposomal amphotericin B for empirical antifungal therapy.
2002 May 30
Voriconazole versus liposomal amphotericin B for empirical antifungal therapy.
2002 May 30
Voriconazole versus liposomal amphotericin B for empirical antifungal therapy.
2002 May 30
Voriconazole -- better chances for patients with invasive mycoses.
2002 May 31
Management of mycoses in patients with hematologic disease and cancer -- review of the literature.
2002 May 31
Management of mycoses in surgical patients -- review of the literature.
2002 May 31
Gateways to clinical trials.
2002 Nov
In vitro susceptibilities of cerebrospinal fluid isolates of Cryptococcus neoformans collected during a ten-year period against fluconazole, voriconazole and posaconazole (SCH56592).
2002 Nov
An unusual case of pulmonary invasive aspergillosis and aspergilloma cured with voriconazole in a patient with cystic fibrosis.
2002 Nov 1
The safety of voriconazole.
2002 Nov 15
[Antifungal treatments].
2002 Nov 30
In vitro activities of investigational triazoles against Fusarium species: effects of inoculum size and incubation time on broth microdilution susceptibility test results.
2002 Oct
Voriconazole treatment of disseminated paecilomyces infection in a patient with acquired immunodeficiency syndrome.
2002 Oct 1
Pseudallescheria boydii (Anamorph Scedosporium apiospermum). Infection in solid organ transplant recipients in a tertiary medical center and review of the literature.
2002 Sep
Cerebral aspergillosis caused by Neosartorya hiratsukae, Brazil.
2002 Sep
Determination of voriconazole in aqueous humor by liquid chromatography-electrospray ionization-mass spectrometry.
2002 Sep 5
Emergence of nosocomial candidemia at a teaching hospital in Taiwan from 1981 to 2000: increased susceptibility of Candida species to fluconazole.
2002 Winter
Characterization of a lanosterol 14 alpha-demethylase from Pneumocystis carinii.
2003 Aug
Successful control of disseminated Scedosporium prolificans infection with a combination of voriconazole and terbinafine.
2003 Feb
In vitro activity of voriconazole, itraconazole, caspofungin, anidulafungin (VER002, LY303366) and amphotericin B against aspergillus spp.
2003 Feb
Antifungal pharmacotherapy for invasive mould infections.
2003 Feb
Disseminated infection due to Cylindrocarpon (Fusarium) lichenicola in a neutropenic patient with acute leukaemia: report of a case and review of the literature.
2003 Jan
In vitro activities of voriconazole, posaconazole, and four licensed systemic antifungal agents against Candida species infrequently isolated from blood.
2003 Jan
Activity of voriconazole against corneal isolates of Scedosporium apiospermum.
2003 Jan
In vitro susceptibilities of zygomycetes to conventional and new antifungals.
2003 Jan
Arthritis and osteomyelitis due to Aspergillus fumigatus: a 17 years old boy with chronic granulomatous disease.
2003 Jan 31
Voriconazole: a new triazole antifungal agent.
2003 Mar 1
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment:: I.V. for Injection requires reconstitution to 10 mg/mL and subsequent dilution to 5 mg/mL or less prior to administration as an infusion, at a maximum rate of 3 mg/kg per hour over 1-2 hours
Tablets should be taken at least one hour before, or one hour following, a meal.
Route of Administration: Oral
In Vitro Use Guide
Curator's Comment:: The in vitro data obtained suggest that voriconazole may be effective in the treatment of opportunistic fungal infections.These investigators also noted that voriconazole was significantly more effective than itraconazole in reducing Aspergillus content in the lungs of immunocompromised animals with pulmonary aspergillosis.
each microdilution well containing 100 ul of the drug concentrations was inoculated with 100 ul of the diluted inoculum suspension (final volume in each well was 200 ul). Drug concentrations were 0.03 to 16 mg/ml for voriconazole. Stock inoculum suspensions of the molds were prepared from 7-day (Aspergillus spp., Bipolaris spp., P. boydii, R. arrhizus, and S. schenckii) or 7- to 10-day (B. dermatitidis and H. capsulatum) cultures grown on PDA at 35°C (cultures for Fusarium spp. were grown at 35°C for 48 to 72 h and then at 25 to 28°C until day 7
Substance Class Chemical
Created
by admin
on Fri Jun 25 21:08:32 UTC 2021
Edited
by admin
on Fri Jun 25 21:08:32 UTC 2021
Record UNII
JFU09I87TR
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
VORICONAZOLE
EMA EPAR   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP-RS   VANDF   WHO-DD  
INN   USAN  
Official Name English
4-PYRIMIDINEETHANOL, A-(2,4-DIFLUOROPHENYL)-5-FLUORO-.BETA.-METHYL-.ALPHA.-(1H-1,2,4-TRIAZOL-1-YLMETHYL)-, (.ALPHA.R,.BETA.S)-
Common Name English
VORICONAZOLE [ORANGE BOOK]
Common Name English
UK-109,496
Code English
VORICONAZOLE [INN]
Common Name English
UK-109496
Code English
(.ALPHA.R,.BETA.S)-A-(2,4-DIFLUOROPHENYL)-5-FLUORO-.BETA.-METHYL-.ALPHA.-(1H-1,2,4-TRIAZOL-1-YLMETHYL)-4-PYRIMIDINEETHANOL
Common Name English
VORICONAZOLE [JAN]
Common Name English
VORICONAZOLE [WHO-DD]
Common Name English
VORICONAZOLE [USP-RS]
Common Name English
VFEND
Brand Name English
NSC-759888
Code English
VORICONAZOLE [MART.]
Common Name English
VORICONAZOLE [EMA EPAR]
Common Name English
VORICONAZOLE [MI]
Common Name English
VORICONAZOLE [USAN]
Common Name English
VORICONAZOLE [EP MONOGRAPH]
Common Name English
VORICONAZOLE [USP MONOGRAPH]
Common Name English
VORICONAZOLE [VANDF]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C514
Created by admin on Fri Jun 25 21:08:32 UTC 2021 , Edited by admin on Fri Jun 25 21:08:32 UTC 2021
NDF-RT N0000008217
Created by admin on Fri Jun 25 21:08:32 UTC 2021 , Edited by admin on Fri Jun 25 21:08:32 UTC 2021
WHO-ATC J02AC03
Created by admin on Fri Jun 25 21:08:32 UTC 2021 , Edited by admin on Fri Jun 25 21:08:32 UTC 2021
WHO-VATC QJ02AC03
Created by admin on Fri Jun 25 21:08:32 UTC 2021 , Edited by admin on Fri Jun 25 21:08:32 UTC 2021
NDF-RT N0000175487
Created by admin on Fri Jun 25 21:08:32 UTC 2021 , Edited by admin on Fri Jun 25 21:08:32 UTC 2021
LIVERTOX 1039
Created by admin on Fri Jun 25 21:08:32 UTC 2021 , Edited by admin on Fri Jun 25 21:08:32 UTC 2021
Code System Code Type Description
RXCUI
121243
Created by admin on Fri Jun 25 21:08:32 UTC 2021 , Edited by admin on Fri Jun 25 21:08:32 UTC 2021
PRIMARY RxNorm
MESH
C102790
Created by admin on Fri Jun 25 21:08:32 UTC 2021 , Edited by admin on Fri Jun 25 21:08:32 UTC 2021
PRIMARY
DRUG BANK
DB00582
Created by admin on Fri Jun 25 21:08:32 UTC 2021 , Edited by admin on Fri Jun 25 21:08:32 UTC 2021
PRIMARY
NDF-RT
N0000182140
Created by admin on Fri Jun 25 21:08:32 UTC 2021 , Edited by admin on Fri Jun 25 21:08:32 UTC 2021
PRIMARY Cytochrome P450 2C19 Inhibitors [MoA]
EVMPD
SUB00087MIG
Created by admin on Fri Jun 25 21:08:32 UTC 2021 , Edited by admin on Fri Jun 25 21:08:32 UTC 2021
PRIMARY
ChEMBL
CHEMBL638
Created by admin on Fri Jun 25 21:08:32 UTC 2021 , Edited by admin on Fri Jun 25 21:08:32 UTC 2021
PRIMARY
CAS
137234-62-9
Created by admin on Fri Jun 25 21:08:32 UTC 2021 , Edited by admin on Fri Jun 25 21:08:32 UTC 2021
PRIMARY
EPA CompTox
137234-62-9
Created by admin on Fri Jun 25 21:08:32 UTC 2021 , Edited by admin on Fri Jun 25 21:08:32 UTC 2021
PRIMARY
MERCK INDEX
M11501
Created by admin on Fri Jun 25 21:08:32 UTC 2021 , Edited by admin on Fri Jun 25 21:08:32 UTC 2021
PRIMARY Merck Index
NCI_THESAURUS
C1707
Created by admin on Fri Jun 25 21:08:32 UTC 2021 , Edited by admin on Fri Jun 25 21:08:32 UTC 2021
PRIMARY
INN
7269
Created by admin on Fri Jun 25 21:08:32 UTC 2021 , Edited by admin on Fri Jun 25 21:08:32 UTC 2021
PRIMARY
NDF-RT
N0000185504
Created by admin on Fri Jun 25 21:08:32 UTC 2021 , Edited by admin on Fri Jun 25 21:08:32 UTC 2021
PRIMARY Cytochrome P450 2C9 Inhibitors [MoA]
USP_CATALOG
1718008
Created by admin on Fri Jun 25 21:08:32 UTC 2021 , Edited by admin on Fri Jun 25 21:08:32 UTC 2021
PRIMARY USP-RS
FDA UNII
JFU09I87TR
Created by admin on Fri Jun 25 21:08:32 UTC 2021 , Edited by admin on Fri Jun 25 21:08:32 UTC 2021
PRIMARY
PUBCHEM
71616
Created by admin on Fri Jun 25 21:08:32 UTC 2021 , Edited by admin on Fri Jun 25 21:08:32 UTC 2021
PRIMARY
DRUG CENTRAL
2846
Created by admin on Fri Jun 25 21:08:32 UTC 2021 , Edited by admin on Fri Jun 25 21:08:32 UTC 2021
PRIMARY
NDF-RT
N0000182141
Created by admin on Fri Jun 25 21:08:32 UTC 2021 , Edited by admin on Fri Jun 25 21:08:32 UTC 2021
PRIMARY Cytochrome P450 3A4 Inhibitors [MoA]
Related Record Type Details
METABOLIC ENZYME -> SUBSTRATE
IN VITRO
BINDER->LIGAND
Plasma protein binding is estimated to be 58% and was shown to be independent of plasma concentrations achieved following single and multiple oral doses of 200 mg or 300 mg (approximate range: 0.9-15 mg/ml).
BINDING
METABOLIC ENZYME -> SUBSTRATE
IN VITRO
METABOLIC ENZYME -> INHIBITOR
IC50
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
EP
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
METABOLIC ENZYME -> SUBSTRATE
IN VITRO
METABOLIC ENZYME -> INHIBITOR
IC50
EXCRETED UNCHANGED
URINE
METABOLIC ENZYME -> INHIBITOR
IC50
METABOLIC ENZYME -> SUBSTRATE
Related Record Type Details
METABOLITE LESS ACTIVE -> PARENT
MAJOR
PLASMA
METABOLITE LESS ACTIVE -> PARENT
METABOLITE LESS ACTIVE -> PARENT
MAJOR
PLASMA
METABOLITE -> PARENT
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
For the calculation of contents, multiply the peak areas by 2.1
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
For the calculation of contents, multiply the peak areas by 0.7
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
For the calculation of contents, multiply the peak areas by 0.7
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
ORAL BIOAVAILABILITY PHARMACOKINETIC
Cmax PHARMACOKINETIC Dose

Route

Biological Half-life PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC AT STEADY-STATE

Tmax PHARMACOKINETIC